Written		Answers	[16 I	DEC. 1985]	to Que	222	
(1)	(2)		(3)	(4)	(5)	(6)	(7)
II. Dexy	vcycline .						• .
(i)	I.D.P.L.		5.00	Basic	10.0	••	
(ii)	Ranbaxy		2.50	**	o· 68	ı·66	4.32
111. Ery	thromycin	• • • • • • • • • • • • • • • • • • • •		•			
(i)	I.D.P.L.		36∙ 00	Basic	• •	1. 10	••
(ii)	Gujarat Th Bioeyen	emis	40-00	Intermediate	15.42	12 66	10, 11
(iii)	Alembic Ch	emicals	12.00	Basic	14: 70	17.75	9.00
(iv)	Standard F ticals	harmac-n-	6.00	"		••	••
IV. Amp	picillin						,
(i)	I.D.P.L.		35.00	Basic	1.00	o· 26	3.7
(ii)	H.A.L.		35.00	**	14-18	8.38	13.56
(iii)	Ranbaxy		*55*50	Intermediate	44 · 89	45. 03	65· 70
(iv)	Alembic		5.00	Basic	2.42	2-48	t · 65
(v)	Cadila Lab	s	2:00	Intermediate		0.29	13.61
' (vi)	Lyphin Che	em	••	33	••	••	6-45
V. Amox	i cillin					•	
(i)	I.D.P.L.		25	Basic	g· 90	2. 10	1-30
, (ii)	H.A.L.			••	• •	••	••
(iii)	Sarabhai Cl	iemicals	6	Basic		••	0.17
(iv)	Ranbaxy		*55-50	Intermediate		• •	0.11

[16 DEC 1095]

*Overall canacity.

Bulk drugs under category I and II

Written Anguard

221

2827. SHRI PRAVIN KUMAR PRAJAPATI: Will the Minister of INDUSTRY be pleased to state:

- (a) names of the bulk drugs, which fall under category I and II Drugs Price Control Order being produced by Hoechst, Pfizer, Glaxo, Merck. Sharp, Roche, Ethenor, Geoffary Manner, Fairdeal Corporation. Wockhardt, F. Merck and Organon;
- (b) what is the licensed capacity and •what was the production during the last three years, yearwise of each drug;

(c) what is the price fixed of each by Government and charged by each of these companies;

to Ougstions

222

- (d) names of drug which fall under price exempted category produced by each of these companies along with licensed capacity and production during the last three years, yearwise;
- (e) names of formulations based on these drugs along with selling price of each during 1979 and 1985; and
- (f) names of drugs where production exceeded than the permitted capacity which falls under category III and IV of these companies?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) and (b) A Statement giving the details of Category I and II bulk drugs produced by the

Written Answers

companies referred to and other details as asked for is attached.

to Questions

(c) The prices fixed for the drugs under Drugs (Prices Control) Order, 1979 referred to in the Statement are given below:-

SI. No.	Name of the	Bulk 1	Drug				-	·	:	-	Price fixed under DPCC, 1979 (Rs./Kg.)
1	Frusemide				•		.•	٠.		··.	1426-13
2	Tolbutamide	: `		•	· .	٠.		•	•	•	125 82
3	Sodium PAS	•			•	•	•	•		•	116.80

Based on the stay granted by the Delhi High Court Mis. Hoechst India Limited are charging a price of Rs. 1679,47 for Frusemide. In respect of other bulk drugs

no reports of overcharging of the prices. have been received.

(d) to (f) Information to the extent available would be collected and taid on the Table of the Rajya Sabha

Statement

(Figures in tonnes)

SI. No.	Name of the Company	Name of the Bulk	Licensed	Production during the last 3 years			
		Drug	Capacity	1982-83	1983-84	1984-85	
1	2	3	4	5	6	7	
1	Hoochst India Limited	Frusemide	7. 18	4.19	8.92	6.73	
•	Do.	To:butamide	72	24.64	21.58	18.01	
3	Pfizer Limited	Sodium PAS	110	12.60	3.67	8.52	
4	Glazo Labs	Tripple Antigen	N.A.	1 · 20 (KL)	1.43 (KL)	1·50 (KL)	

Sales him over of vitamin preparations etc.

2828. SHRI PRAV1N **KUMAR** PRAJAPATI; Will the Minister of IN-DUSTRY be pleased to state:

- (a) what was the annual sales turn over of vitamin preparations. Iron preparations, Appetite stimulants and tonics of Abbott, Glaxo, Pfizer, Bayer, Marind, Merck, Parke Davis, Hoechst and Tthanor during the last three years, year-wise;
- (b) what was the percentage of sales of above mentioned products of each heading of preparations to their total sales turn over during the above meniioned period;
- (c) what was the price of each formulation of above mentioned preparations during 1980 and 1985;
- (d) which are the products being marketed by these companies under price exempted category or without price approval along with name composition and therapeutic indication of each; and